drugset / Trial / NCT05924412

Parecoxib in Total Knee Arthroplasty

NCT05924412

Phase 4 Completed 40 enrolled University of Chile
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Early mobilization and rehabilitation can be difficult after total knee arthroplasty (TKA) due to a high incidence of moderate to severe postoperative pain. Non-steroidal anti-inflammatory drugs (NSAIDs) are important to multimodal analgesic protocols. Parecoxib is an NSAID that selectively inhibits the enzyme cyclooxygenase-2 (COX-2). Clinical trials have shown that it does not alter platelet function or gastric mucosa. A recent study, after comparing ketorolac and parecoxib used at the same time in infiltration and systemically, found no differences in perioperative analgesia with a tendency to less bleeding in the parecoxib group. This randomized study will compare the effectiveness of adding a COX-2 inhibitor in the pain management of patients undergoing TKA as part of a multimodal analgesia regimen. The morphine consumption was selected as the primary outcome. The study hypothesis is that patients receiving parecoxib would have a lower opioid consumption.

Timeline

Start
2023-07-06
Primary completion
2024-09-01
Completion
2024-09-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Parecoxib Small molecule 40 mg Intravenous